Mayo expansion comes at a price; earnings drop 35 percent

Mayo Clinic's net income dropped 35 percent after it made acquisitions and borrowed to fund projects.

February 23, 2013 at 3:08AM
Main entrance to the Gonda Building. For more than a century, the city of Rochester has been shaped and defined by the Mayo Clinic. Now the Mayo has a $6 billion vision to reshape the city and itself.Wednesday, February 21, 2013 ] GLEN STUBBE * gstubbe@startribune.com
The Mayo Clinic's Gonda Building in Rochester (The Minnesota Star Tribune)

The Mayo Clinic's expansion plans are crimping its financial results and raising a note of concern from one of the nation's top ratings agencies.

Audited financial documents filed this week showed that net income in 2012 dropped 35 percent to $395.4 million compared with a year earlier, as the Rochester-based medical organization purchased clinics in Red Wing, Minn., and Waycross, Ga., and took on $300 million in bonds to fund several construction projects.

Mayo remains a well-funded operation, however. Consolidated revenue ticked up 6.3 percent to $8.84 billion, results that also include a clinic system that covers more than 70 communities in the Midwest and hospitals in Scottsdale, Ariz., and Jacksonville, Fla.

Ratings agency Standard & Poor affirmed its AA rating for Mayo's long-term debt, a step below its highest rating, and said the rating reflects S&P's assessment of "Mayo Clinic's excellent enterprise profile" and "international reputation."

However, S&P also revised Mayo's rating outlook to "negative" based on the additional debt, a slowdown in revenue growth and about $1.2 billion in unfunded pension obligations.

In determining a ratings outlook, S&P says it considers any changes in economic and fundamental business conditions.

A change in the outlook is not necessarily a precursor of a rating change, which is a measure of an organization's creditworthiness, but it also is not uncommon for the agencies to adjust an outlook in advance of a forthcoming change.

"We revised the outlook to reflect our opinion of Mayo Clinic's weaker operating performance, especially in the second half of 2012, and additional debt with this issue, which we did not expect and did not include in our last rating analysis," S&P credit analyst Martin Arrick said in a statement issued Wednesday.

Mayo is charting what it believes could be a $6 billion remake of southeastern Minnesota and the downtown area around its flagship medical center over the coming decade.

The organization is lobbying state lawmakers for $585 million in taxpayer support to pay for infrastructure costs, as Mayo pays for $3.5 billion in capital projects.

Several major building projects, including a proton beam therapy center and expansion of a wellness facility, are underway and a few are waiting in the wings, including an overhauled emergency department at St. Marys Hospital.

With start-up costs for the projects and pension obligations, growth in expenditures has outstripped growth in revenue. Standard & Poor noted that the investments may not produce net improvements in operating income for a few years.

Mayo officials plan to offer a fuller explanation of its financial performance Wednesday. But a spokesman said Mayo is taking advantage of favorable interest rates as it seeks to expand, which may have a short-term impact on cash flow. The spokesman said the organization's operating margins are in line with its annual target of 4 to 6 percent.

Jackie Crosby • 612-673-7335

about the writer

about the writer

Jackie Crosby

Reporter

Jackie Crosby is a general assignment business reporter who also writes about workplace issues and aging. She has also covered health care, city government and sports. 

See Moreicon

More from Business

See More
card image
Fairview Health Services

The school is changing an elective course while still working with the Eden Prairie-based health care giant after students raised concerns.

This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in the lab. (NIAID/TNS) ORG XMIT: 1659810
card image